Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $902.3 million.

  • Ani Pharmaceuticals' Total Liabilities rose 534.17% to $902.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $902.3 million, marking a year-over-year increase of 534.17%. This contributed to the annual value of $855.2 million for FY2024, which is 9138.83% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Total Liabilities is $902.3 million, which was up 534.17% from $881.4 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Total Liabilities high stood at $902.3 million for Q3 2025, and its period low was $260.1 million during Q1 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median Total Liabilities value was $425.7 million (recorded in 2023), while the average stood at $517.5 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first crashed by 744.68% in 2021, then surged by 10025.17% in 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Total Liabilities (Quarter) stood at $412.9 million in 2021, then rose by 2.1% to $421.5 million in 2022, then grew by 6.0% to $446.8 million in 2023, then surged by 91.39% to $855.2 million in 2024, then increased by 5.52% to $902.3 million in 2025.
  • Its last three reported values are $902.3 million in Q3 2025, $881.4 million for Q2 2025, and $849.0 million during Q1 2025.